SOLO-1 trial: Olaparib maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer
The results from the phase III SOLO-1 trial testing Olaparib ( Lynparza ) tablets as a maintenance treatment for patients with newly-diagnosed, advanced BRCA-mutated ( BRCAm ) ovarian cancer who were ...
read article